AstraZeneca: Imfinzi Approved in China for Stage III Nonsmall-Cell Lung Cancer

Date : 12/12/2019 @ 7:53AM
Source : Dow Jones News
Stock : AstraZeneca PLC (AZN)
Quote : 42.47  0.0 (0.00%) @ 9:18AM

AstraZeneca: Imfinzi Approved in China for Stage III Nonsmall-Cell Lung Cancer

Astrazeneca (LSE:AZN)
Historical Stock Chart

6 Months : From Sep 2019 to Mar 2020

Click Here for more Astrazeneca Charts.
   By Adriano Marchese 
 

AstraZeneca PLC (AZN.LN) said Thursday that it has received marketing authorization from China's national medical products administration for Imfinzi for the treatment of patients with stage III nonsmall-cell lung cancer.

The U.K. pharmaceuticals company said approval of Imfinzi is based on results from the primary analysis of progression-free survival and supported by overall survival from the Phase III Pacific trial.

 

Write to Adriano Marchese at adriano.marchese@wsj.com

 

(END) Dow Jones Newswires

December 12, 2019 02:38 ET (07:38 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest AZN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


$
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.